drugset / Trial / NCT04671875
A Clinical Study of MIL93 in Solid Tumors.
NaSingle-groupOpen-labelTreatment
Summary
MIL93 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open label Phase I study to evaluate safety, tolerability, pharmacokinetics and efficacy of MIL93 in Advanced or Metastatic solid tumors.
Timeline
- Start
- 2021-04-21
- Primary completion
- 2025-08
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MIL93 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | MIL93 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | MIL93 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | MIL93 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | MIL93 | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | MIL93 | Monoclonal antibody | 30 mg/kg | Intravenous |